Compare GT & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | MPLT |
|---|---|---|
| Founded | 1898 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2005 | N/A |
| Metric | GT | MPLT |
|---|---|---|
| Price | $5.71 | $27.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $9.13 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 8.9M | 249.6K |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,280,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.43 | $12.24 |
| 52 Week High | $12.03 | $33.28 |
| Indicator | GT | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 46.56 |
| Support Level | $5.43 | $26.20 |
| Resistance Level | $6.26 | $31.88 |
| Average True Range (ATR) | 0.19 | 2.22 |
| MACD | 0.01 | -0.24 |
| Stochastic Oscillator | 27.71 | 38.99 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.